{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:49:03Z","timestamp":1762249743161,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102589","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T13:51:33Z","timestamp":1603115493000},"page":"102589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab"],"prefix":"10.1016","volume":"46","author":[{"given":"Ivan","family":"Adamec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijana","family":"\u0106ori\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berislav","family":"Ru\u0161ka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-1748","authenticated-orcid":false,"given":"Mario","family":"Habek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102589_bib0001","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.msard.2018.12.005","article-title":"Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease","volume":"27","author":"Alcal\u00e1","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2020.102589_bib0002","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2020.102589_bib0003","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2020.102589_bib0004","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1007\/s00415-018-8822-y","article-title":"Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations","volume":"265","author":"Devonshire","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2020.102589_bib0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.msard.2020.102589_bib0006","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.molmed.2017.05.006","article-title":"Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective","volume":"23","author":"Moulton","year":"2017","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.msard.2020.102589_bib0007","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.msard.2020.102589_bib0008","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2020.102589_bib0009","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.msard.2020.102589_bib0010","doi-asserted-by":"crossref","first-page":"e635","DOI":"10.1212\/NXI.0000000000000635","article-title":"Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab","volume":"7","author":"Wiendl","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2020.102589_bib0011","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1177\/1352458518790391","article-title":"Sarcoidosis following alemtuzumab treatment for multiple sclerosis","volume":"24","author":"Willis","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2020.102589_bib0012","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40263-020-00749-x","article-title":"Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study","volume":"34","author":"Ziemssen","year":"2020","journal-title":"CNS Drugs"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820306635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820306635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:58:46Z","timestamp":1761901126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820306635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":12,"alternative-id":["S2211034820306635"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102589","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102589"}}